| Christopher A Enoch, DO | |
|
1340 Belmont Ave, Suite 2300, Youngstown, OH 44504-1125 | |
| (330) 746-1488 | |
| (330) 746-5611 |
| Full Name | Christopher A Enoch |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 27 Years |
| Location | 1340 Belmont Ave, Youngstown, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912978503 | NPI | - | NPPES |
| 01766337 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 34007892E (Ohio) | Primary |
| 207RN0300X | Internal Medicine - Nephrology | OS010186L (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fresenius Medical Care Hermitage | Hermitage, PA | Dialysis facility |
| Fresenius Medical Care New Castle | New castle, PA | Dialysis facility |
| Sharon Regional Health System | Sharon, PA | Hospital |
| Upmc Horizon | Greenville, PA | Hospital |
| Upmc Jameson | New castle, PA | Hospital |
| Butler Memorial Hospital | Butler, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Kidney Group Inc | 0941291231 | 19 |
| The Kidney Group Inc | 0941291231 | 19 |
News Archive
One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Gemcitabine HCI for Injection, USP, in the 2 g dosage strength. APP will launch this presentation of Gemcitabine immediately.
Aflac Incorporated today reported its fourth quarter results. Reflecting the weaker yen/dollar exchange rate, revenues rose 6.6% to $6.4 billion in the fourth quarter of 2012, compared with $6.0 billion in the fourth quarter of 2011. Net earnings were $581 million, or $1.24 per diluted share, compared with $538 million, or $1.15 per share, a year ago.
Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.
› Verified 1 days ago
| Entity Name | The Kidney Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982741971 PECOS PAC ID: 0941291231 Enrollment ID: O20050421000747 |
News Archive
One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Gemcitabine HCI for Injection, USP, in the 2 g dosage strength. APP will launch this presentation of Gemcitabine immediately.
Aflac Incorporated today reported its fourth quarter results. Reflecting the weaker yen/dollar exchange rate, revenues rose 6.6% to $6.4 billion in the fourth quarter of 2012, compared with $6.0 billion in the fourth quarter of 2011. Net earnings were $581 million, or $1.24 per diluted share, compared with $538 million, or $1.15 per share, a year ago.
Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher A Enoch, DO 1340 Belmont Ave, Suite 2300, Youngstown, OH 44504-1125 Ph: (330) 746-1488 | Christopher A Enoch, DO 1340 Belmont Ave, Suite 2300, Youngstown, OH 44504-1125 Ph: (330) 746-1488 |
News Archive
One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Gemcitabine HCI for Injection, USP, in the 2 g dosage strength. APP will launch this presentation of Gemcitabine immediately.
Aflac Incorporated today reported its fourth quarter results. Reflecting the weaker yen/dollar exchange rate, revenues rose 6.6% to $6.4 billion in the fourth quarter of 2012, compared with $6.0 billion in the fourth quarter of 2011. Net earnings were $581 million, or $1.24 per diluted share, compared with $538 million, or $1.15 per share, a year ago.
Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.
› Verified 1 days ago
Dr. Khaled Al-taieb, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 465 Gypsy Ln Apt 407, Youngstown, OH 44504 Phone: 330-391-0462 | |
Dr. Michael Allen Van Winkle, D.O Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1044 Belmont Ave, Youngstown, OH 44504 Phone: 330-480-3676 Fax: 330-480-7979 | |
Dr. Ayesha Khadka, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: St. Elizabeth Youngstown Hospital, Internal Medicine, 1001 Covington St. Youngstown, Youngstown, OH 44510 Phone: 330-480-2616 | |
Dr. Ghazaleh Bigdeli, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 925 Trailwood Dr, Youngstown, OH 44512 Phone: 330-758-7575 | |
Dr. Jeffrey C Halley, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 250 Debartolo Pl, Suite 2750, Youngstown, OH 44512 Phone: 330-758-7703 Fax: 330-758-4930 | |
Dr. Masud R Bhatti, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 835 Southwestern Run, Youngstown, OH 44514 Phone: 330-318-1100 | |
Chakri Yarlagadda, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1001 Belmont Ave, Youngstown, OH 44504 Phone: 330-747-6446 Fax: 330-747-6843 |